Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke

This noninferiority randomized clinical trial investigates whether tenecteplase is noninferior to alteplase for the treatment of Chinese patients with acute ischemic stroke eligible for intravenous thrombolysis within 4.5 hours after symptom onset.